PlexusDx supports precision-focused discussions by helping you explore both clinical markers and genetic predispositions in peptide pathways, enabling a more personalized conversation with your provider about whether GLP-1 aligns with your health goals
Free Resource: 7 Steps to Quiet Food Noise Ive created a free download to help you apply these strategies
Semaglutide GLP-1 belongs to a category of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, often referred to as incretin mimetics. By imitating the function of GLP-1, a natural hormone in our bodies, Semaglutide GLP-1 plays an important role in controlling blood sugar levels, reducing appetite, and slowing down gastric emptying all of which can contribute to weight loss
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Cold turkey vs
PlexusDx coordinates with your healthcare provider to adjust therapy based on your response and genetic insights, ensuring you avoid prolonged plateaus and achieve your personal weight loss goals
